Praxis develops therapies for CNS disorders by leveraging genetic insights into neuronal imbalances, targeting rare to common conditions.
Praxis Precision Medicines has raised $575.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in January 2026.
Praxis Precision Medicines's investors include Blackstone Life Sciences, Vida Ventures, Cormorant Asset Management, Novo Holdings, Qatar Investment Authority.
Praxis Precision Medicines is headquartered in Cambridge, United States.
Praxis develops therapies for CNS disorders by leveraging genetic insights into neuronal imbalances, targeting rare to common conditions.
Praxis Precision Medicines is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Praxis Precision Medicines — Funding & Investors." VCBacked, January 6, 2026, https://www.vcbacked.co/company/praxis-precision-medicines. Accessed July 20, 2026.
VCBacked. (2026). Praxis Precision Medicines — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/praxis-precision-medicines
{{cite web |title=Praxis Precision Medicines — Funding & Investors |url=https://www.vcbacked.co/company/praxis-precision-medicines |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated